Bullish View Expects Sterilization Demand And Cobalt 60 Stability To Support Long-Term Upside

Catalysts

About Sotera Health

Sotera Health provides sterilization services and lab testing that support global health care and medical products.

What are the underlying business or industry changes driving this perspective?

• Growing demand from core medical device and bioprocessing customers is supporting consistent volume growth at Sterigenics, which directly supports revenue and adjusted EBITDA.
• Nordion’s 25 year Class 1B license renewal underpins long term availability of Cobalt 60 for sterilization and radiotherapy, which can support stable revenue streams and high segment income margins.
• Increased pricing power across Sterigenics and Nordion, with company wide price expected near the midpoint of a 3% to 4% range for 2025, is a tailwind for revenue and adjusted EBITDA margins.
• Regulatory driven testing needs such as extractables and leachables and bioprocessing related work at Nelson Labs are supporting growth in core lab testing, which is already contributing to segment income expansion and higher net margins.
• Visibility on Cobalt 60 supply and the absence of 2025 revenue risk for this material reduce uncertainty for customers, which can support contract stability, cash generation and earnings quality.
• Ongoing improvement in net leverage, interest expense and free cash flow, including an expected US$500m to US$600m cumulative free cash flow from 2025 to 2027, increases financial flexibility to support earnings through lower interest costs.

Assumptions

This narrative explores a more optimistic perspective on Sotera Health compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts. How have these above catalysts been quantified?

• The bullish analysts are assuming Sotera Health's revenue will grow by 6.9% annually over the next 3 years.
• The bullish analysts assume that profit margins will increase from 4.8% today to 18.3% in 3 years time.
• The bullish analysts expect earnings to reach $257.6 million (and earnings per share of $0.89) by about January 2029, up from $55.4 million today. The analysts are largely in agreement about this estimate.
• In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 34.3x on those 2029 earnings, down from 94.9x today. This future PE is lower than the current PE for the US Life Sciences industry at 36.0x.
• The bullish analysts expect the number of shares outstanding to grow by 0.22% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 8.74%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Long-running ethylene oxide personal injury and public nuisance litigation in multiple states, including Georgia, New Mexico and California with 83 personal injury claims in California and an Attorney General case in New Mexico, could result in higher legal costs, settlement payments or operational restrictions for Sterigenics, which would pressure earnings and net margins over time.
• Persistent weakness in Nelson Labs Expert Advisory Services, which management links to reduced FDA activity and funding, may limit the ability of the Nelson segment to return to broad based growth even as core lab testing performs better. This could put a cap on consolidated revenue growth and limit further margin expansion.
• The inherent lumpiness of Nordion’s Cobalt 60 and equipment sales, driven by reactor harvest schedules and customer delivery timing, can create quarters of softer volumes and less favorable product mix. This may weigh on Nordion’s segment income margin and introduce volatility into total company revenue and earnings.
• If pricing benefits in Sterigenics and Nordion settle at the lower end of the company’s 3% to 4% long term range or if customers resist further price adjustments tied to regulatory capital investments such as NESHAP related upgrades, the company could see slower revenue growth while inflation and higher operating costs continue. This would compress adjusted EBITDA margins and net income.
• Although net leverage has been trending lower, the company still carries a material interest expense of US$154m to US$158m for 2025 and remains above its long term 2x to 3x net leverage target. Any slowdown in adjusted EBITDA growth or cash generation would delay deleveraging and keep interest costs elevated, limiting growth in earnings per share.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bullish price target for Sotera Health is $24.0, which represents up to two standard deviations above the consensus price target of $20.44. This valuation is based on what can be assumed as the expectations of Sotera Health's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $24.0, and the most bearish reporting a price target of just $16.0.
  
• In order for you to agree with the more bullish analyst cohort, you'd need to believe that by 2029, revenues will be $1.4 billion, earnings will come to $257.6 million, and it would be trading on a PE ratio of 34.3x, assuming you use a discount rate of 8.7%.
  
• Given the current share price of $18.51, the analyst price target of $24.0 is 22.9% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.